INVESTORS & MEDIA
Sanofi and Regeneron Report Positive Results With Alirocumab From Phase 2 Japanese Study
At Week 12, the mean percentage reduction in LDL-C from baseline in patients receiving alirocumab 50 mg Q2W was 55 percent, alirocumab 75 mg Q2W was 62 percent and alirocumab 150 mg Q2W was 72 percent, compared to 3 percent in the placebo group (p < 0.0001 vs. placebo for all treatment arms). All patients in each of the alirocumab groups achieved LDL-C levels of < 100 mg/dL, compared to 8 percent of patients in the placebo group.
Treatment emergent adverse events (TEAEs) in this study were reported by 52 percent of patients in the alirocumab 50 mg group, 48 percent of patients in the 75 mg group, 64 percent of patients in the 150 mg group, compared to 32 percent in the placebo group. The most frequently reported TEAEs were nasopharyngitis, injection site reaction, back pain, cystitis and ligament sprain.
"We are delighted with the findings from the first Phase 2 trial with alirocumab in Japanese patients. Not only was alirocumab shown, in this study, to significantly reduce LDL-C in this patient population, the results of this study also demonstrate the potential efficacy of alirocumab at a range of doses," said
"Hypercholesterolemia is a growing problem in
About the Alirocumab Phase 2 Japanese Study
This multicenter, placebo-controlled Phase 2 study randomized approximately 100 patients with LDL-C greater than or equal to 100 mg/dL receiving lipid-modifying therapy. 25 patients per group were randomized to receive one of three doses of alirocumab dosed subcutaneously every other week (Q2W) -- 150 milligrams (mg), 75 mg or 50 mg, or placebo, all in combination with statin therapy.
The primary study endpoint was the percentage change in calculated LDL-C from baseline to Week 12. The secondary study endpoints included absolute change in calculated LDL-C from baseline to Week 12 and percent and absolute changes in other lipid parameters at Week 12.
PCSK9 is known to be a determinant of circulating LDL levels, as it binds to LDL receptors resulting in their degradation so that fewer are available on liver cells to remove excess LDL-C from the blood. Moreover, statins increase the level of circulating PCSK9, which in turn may reduce the density of LDL-C receptors available to clear LDL-C from the circulation. Blocking the PCSK9 pathway is therefore a potentially novel mechanism for lowering LDL-C.
Alirocumab is an investigational, fully-human monoclonal antibody that targets and blocks PCSK9. It is administered via subcutaneous injection. By inhibiting PCSK9, a determinant of circulating LDL-C levels in the blood, alirocumab has been shown in pre-clinical studies to increase the number of LDL receptors on hepatocytes, thereby lowering LDL-C.
The investigational agent described above is currently under clinical development, and its safety and efficacy have not been fully evaluated by any regulatory authority.
Regeneron is a leading science-based biopharmaceutical company based in
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although
Regeneron Forward-Looking Statements
This news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron, and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's products, product candidates, and research and clinical programs now underway or planned, including without limitation alirocumab; unforeseen safety issues resulting from the administration of products and product candidates in patients, including serious complications or side effects in connection with the use of Regeneron's product candidates in clinical trials, including without limitation the Phase 2 trial of alirocumab in Japanese patients and the ODYSSEY global Phase 3 trial program; the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's products and product candidates; competing drugs and product candidates that may be superior to Regeneron's products and product candidates; uncertainty of market acceptance and commercial success of Regeneron's products and product candidates; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; coverage and reimbursement determinations by third-party payers, including
US Media Relations
Tel: 1 (908) 981-5360
Mobile: 1 (908) 340-7811
Tel: +1 914- 847-3358
Tel: +1 914-847-5126
News Provided by Acquire Media